SELLAS Life Sciences (SLS) Operating Leases (2019 - 2026)
SELLAS Life Sciences' (SLS) quarterly Operating Leases came in at $871000.0 in Q1 2026, up 181.88% year-on-year from $309000.0 in Q1 2025, and up 90.59% on a QoQ basis from $457000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Operating Leases (2019 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 8 years of Operating Leases data on file, last reported at $871000.0 in Q1 2026.
- On a quarterly basis, Operating Leases rose 181.88% year-over-year to $871000.0 in Q1 2026; TTM through Mar 2026 was $871000.0, a 181.88% increase from a year earlier, with the FY2025 full-year figure at $457000.0, changed 0.0% from the prior year.
- Operating Leases for Q1 2026 stood at $871000.0, up from $457000.0 in the prior quarter.
- Over the last five years, Operating Leases for SLS reached as high as $1.1 million in Q2 2022 and fell as low as $161000.0 in Q2 2024.
- Historically, Operating Leases has averaged $637437.5 across 5 years, with a median of $610000.0 in 2023.
- Across the five-year window, Operating Leases sank 78.5% in 2024 and jumped 357.76% in 2025, its largest moves.
- Year by year, Operating Leases stood at $573000.0 in 2022, then retreated by 19.72% to $460000.0 in 2023, then decreased by 0.65% to $457000.0 in 2024, then changed by 0.0% to $457000.0 in 2025, then surged by 90.59% to $871000.0 in 2026.
- Per Business Quant data, the three most recent Operating Leases figures were $871000.0 in Q1 2026, $457000.0 in Q4 2025, and $737000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | SELLAS Life Sciences | 3.23 Mn | 3.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 871,000.00 |
| Dec 31, 2025 | 457,000.00 |
| Jun 30, 2025 | 737,000.00 |
| Mar 31, 2025 | 309,000.00 |
| Dec 31, 2024 | 457,000.00 |
| Sep 30, 2024 | 576,000.00 |
| Jun 30, 2024 | 161,000.00 |
| Mar 31, 2024 | 313,000.00 |
| Dec 31, 2023 | 460,000.00 |
| Sep 30, 2023 | 644,000.00 |
| Jun 30, 2023 | 749,000.00 |
| Mar 31, 2023 | 849,000.00 |
| Dec 31, 2022 | 573,000.00 |
| Sep 30, 2022 | 1.04 Mn |
| Jun 30, 2022 | 1.12 Mn |
| Mar 31, 2022 | 883,000.00 |
| Dec 31, 2021 | 610,000.00 |
| Sep 30, 2021 | 857,000.00 |
| Jun 30, 2021 | 903,000.00 |
| Mar 31, 2021 | 949,000.00 |